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         Introduction  
 INTRODUCTION 
 
  Stroke or a cerebrovascular accident is the sudden death of brain cells due to 
the inadequate blood flow. The WHO clinically defines stroke as ' the rapid development of 
clinical signs and symptoms of a focal neurological disturbance lasting more than 24 hours or 
leading to death with no apparent cause other than vascular origin'. Stroke is a clinical 
syndrome which can be sub divided into two broad categories according to its 
pathophysiology. Ischaemic strokes which are caused by either cerebral thrombosis or 
embolism accounting for 50-85% of all strokes worldwide and haemorragic strokes caused by 
subarachnoid haemorrhage or intracerebral haemorrhage and which account for 1%-7% and 
7%-27% respectively of all strokes worldwide. (Balucani et al., 2010). 
 The extent and site of brain injury indicates the effect of stroke but the clinical 
symptoms alone cannot accurately predict its underlying causes. Stroke symptoms involve 
speech impairment, memory loss, acute onset of unilateral paralysis, loss of vision, speech 
impairment, impaired reasoning ability, coma or death. It is found that one third of all strokes 
are preceded by Transient Ischemic attacks(TIAs), also called mini strokes, which are able to 
temporarily interrupt blood flow to the brain. (Balucani et al., 2010). 
  The majority of ischemic strokes are found to be  of arterial origin such as 
atherothrombosis — which is a  generalized, diffuse and progressive polyvascular disease. In 
most of acute ischemic strokes, unstable angina, acute MI, sudden cardiac death, and 
peripheral arterial disease (PAD), atherothrombosis have a key role. (Balucani et al., 2010). 
  The most widely used system of aetiological ischaemic stroke classification is  
Trial of Org 10172 in Acute Stroke Treatment (TOAST) .The TOAST classification system 
has five categories: 1) large-artery atherosclerosis 2) cardioembolism 3) small-artery 
occlusion (lacune) 4) stroke of other determined etiology and 5) stroke of undetermined 
etiology. (Wolf and Hennerici, 2011). 
 
  Antiplatelet therapy remains the cornerstone of therapy for treatment and 
secondary prevention in stroke  because the pathophysiology of stroke involves 
atherosclerotic plaque disruption and subsequent thrombosis. Aspirin exerts its antiplatelet 
action  by irreversibly inhibiting the cyclooxygenase enzyme, blocking the prostaglandin 
mediated pathway of platelet activation. Ticlopidine and clopidogrel,both  thienopyridines 
which are structurally related and  act by selectively inhibiting adenosine diphosphate–
induced platelet aggregation. Dipyridamole has both potent vasodilator and antiplatelet 
activity and act by  by inhibiting phosphodiesterases or blocking uptake of 
adenosine.Epoprostenol ,another potent vasodilator is given to prevent platelet loss during 
renal dialysis.Glycoprotein (GP) IIb-IIIa antagonists, which involve a complex platelet 
glycoprotein IIb- IIIa complex, and mediate platelet aggregation via the binding of adhesive 
proteins such as fibrinogen and von Willebrand factor (vWF).Abciximab is a human-murine 
chimeric monoclonal antibody Fab fragment, which binds to the complex GP IIb-IIIa with 
high affinity.Eptifibatide,Tirofiban and lamifiban are competetive inhibitors of the GP IIb 
IIIa complex.(Bennett and Brown, 2003). 
 
  For preventing recurrent vascular events in patients with a history of stroke or 
TIA, antiplatelet therapy has been proven to be the best strategy available. The advantages of 
secondary stroke prevention associated with aspirin, other antiplatelet agents such as 
clopidogrel and combinations of antiplatelet drugs like aspirin and extended-release 
dipyridamole in preliminary therapy has been recognized by the current clinical practice 
guidelines by  American Heart Association (AHA), American Stroke Association (ASA), 
American College of Chest Physicians (ACCP), American Academy of Neurology (AAN), 
European Stroke  Organization (ESO) and European Society of Cardiology (ESC).There has 
been great developments for the past two decades in antithrombotic agents for secondary 
stroke prevention. (Diener and Wong, 2008). 
 
  A series of trials in stroke prevention with antiplatelets  have been carried out 
in past few years.CAPRIE (Clopidogrel versus Aspirin in Patients at Risk of Ischaemic 
Events) trial  has shown that clopidogrel can better reduce the rate of ischaemic events and 
vascular events than aspirin. (Ringleb et al., 2004). Randomised controlled trials in patients 
with coronary manifestations of atherothrombosis(CURE, CREDO) findings showed the 
sustained benefit of clopidogrel over the  standard treatment including aspirin.               
(Mehta et al., 2001). The therapeutic benefits were all achieved along  with an acceptable 
increase in the risk of major bleeding complications. Thus, these trials gave the  motivation to 
undertake MATCH (Management of ATherothrombosis with Clopidogrel in High-risk 
patients), to find out whether aspirin added to clopidogrel would further reduce the risk of 
recurrent ischaemic vascular events in high-risk patients after transient ischaemic attack or 
ischaemic stroke. (Diener et al., 2004). 
 
  Patients who survive a stroke or TIA are especially vulnerable to recurrent 
cerebrovascular events and most likely to suffer other forms of cardiovascular disease, 
including coronary artery disease, congestive heart failure, atrial fibrillation and peripheral 
vascular disease. The long term stroke recurrence risk ranges from 4-12% annually with a 
particularly heightened risk in first 6 months after an event.These conditions predispose to a 
high term mortality after stroke. Studying the effectiveness of mono and dual antiplatelet 
therapy  will help in improving drug use and thereby increasing  the quality of life in stroke 
patients. 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
       Review  of  Literature 
REVIEW OF LITERATURE 
 
  The World Health Organization(WHO) clinically defines stroke as ―the rapid 
development of clinical signs and symptoms of a focal neurological disturbance lasting more 
than 24 hours or leading to death with no apparent cause other than vascular origin‖ (World 
Health Organization.1989;Sudlow and Warlow.1996). This definition includes cerebral 
infarction, intracerebral hemorrhage and subarachnoid hemorrhage, but excludes transient 
ischemic attack (TIA, which last for 24 hours), subdural or extradural hemorrhage and 
infarction or hemorrhage secondary to infection or malignancy (Bonita, 1992). 
 Hippocrates, the father of medicine, first recognized stroke 2400 years ago. At that 
time stroke was called as apoplexy, which means struck down by violence. However it was 
not until the mid 1600s that Jacob Wepfer found that some of the patients who died with 
apoplexy had bleeding in the brain, while arteries were blocked in some cases. Medical 
science continued to study the cases, symptoms and treatment of apoplexy and finally in 
1928,apoplexy was divided into categories based on the blood vessels involved. Methods like 
contrast angiography and indicator dilution technique used to measure cerebral flow and 
metabolism were developed and first carotid endarterectomy was performed in 1950's.In the 
twentieth century, preventive measures like management of hypertension, use of 
anticoagulant aspirin gained importance. Diagnostic tools like Doppler ultrasonography, CT 
scan, Positron Emission Tomography (PET) scan were performed and implemented. In the 
1980's while the incidence of stroke increased due to drug abuse, there was increased 
emphasis on identifying the risk factors for stroke, especially in women and minorities. 
Cigarette smoking was established as a major risk factor and the cessation of which produced 
a significant risk reduction by two years (National Survey on Drug Use and Health, 2005 
and 2006). That decade also saw improved outcome with early aneurysm surgery, treatment 
and isolated systolic hypertension in the elderly and use of newer drugs and newer diagnostic 
tools like MRI helped to treat and reduce the incidence of stroke. Secondary prevention trials 
emphasized importance of reducing blood pressure and cholesterol. The FDA approved t-
PA,a drug that dissolves clot blocked brain arteries, to treat stroke in the first three hours. The 
addition of dypyridamole, a vasodilator to low dose aspirin was found to increase secondary 
stroke prevention. It was in 1990's that a wealth of information was obtained on the 
prevention and management of stroke through various researches (Stroke Center, 2006). 
Epidemiology of stroke: 
 Approximately, 20 million people suffer from stroke each year and out of these 5 
million will not survive.85% of global deaths from stroke occurs in developing countries. It 
also causes functional impairments, 20% survivors require institutional care after 3 months 
and disability occurs in 15-30%.Stroke is a life-changing event which not only affects the 
person but also his family and caregivers (Balucani, et al., 2010). 
Epidemiological status in Asian countries: 
 Stroke is the major cause of mortality and morbidity in Asian countries (Pandian, et 
al., 2007). In Asian people, intracranial arterial atherosclerotic disease is the more common 
than extra cranial disease (Jiang, et al., 2006). Many studies have shown that there are 
significant racial-ethnic differences in the topographical distribution of atherosclerotic 
lesions.Chinese (Sacco, et al., 1992) Japanese (Mitsuyama, et al., 1979), Hispanics and 
Blacks (Sacco, et al., 1995), have a greater preponderance of intracranial atherosclerosis than 
whites (Kaul, et al., 2002).Within Asians, the reported rates of intracranial stenosis vary. 
Chinese populations showed higher rates than Japanese or Korean populations (Suh, et al., 
2003). A recent study comparing stroke disorders among three Asian races in Singapore 
revealed that Chinese had higher prevalence of stroke when compared to Indians and Malay 
Singaporeans (Venkatasubramanian,et al., 2005). 
Epidemiological status in India : 
 Current demographic trends suggest that the population of India will survive through 
the peak years of occurrence of stroke (age 55-65 years),and stroke survivors in elderly with 
varying degree of residual disability will become a major health burden.In India,a 
multicentric,prospective,hospital based case control study in the west central region revealed 
that diabetes mellitus,hypertension,tobacco use and low hemoglobin rather than cholesterol 
level were the most important risk factors for stroke (Dalal.P.M, 1997). In India, the burden 
of stroke is growing with increasing urbanization pattern (Thammaraj, et al., 2005). The 
estimated deaths due to stroke account for 1.2 % of all the deaths in India (Anand,et al., 
2001). A first community based study on stroke was carried out in and around the town of 
Vellore in South India (Abraham, et al., 1970) during the period of 1969-1971,followed by 
the study in Rohtak in North India during 1971-1974 (Bansal, et al., 1973). A cross sectional 
community based case control study for risk factor analysis on stroke disorders was 
conducted for the first time in the city of Kolkata, demonstrated that hypertension was the 
most important risk factor for stroke (Banerjee, et al., 2001). 
Classification of stroke: 
 Stroke is a clinical syndrome which can be subdivided into two broad categories 
according to its pathophysiology: 
1) Ischemic strokes are caused by either cerebral thrombosis or embolism, accounting for 50-
85% of all strokes worldwide. 
2) Hemorrhagic strokes caused by subarachnoid hemorrhage or intracerebral hemorrhage, 
which account for 1%-7% and 7%-27% respectively of all strokes worldwide. 
I. Ischemic Stroke  
Atherosclerotic cerebrovascular disease (20%) 
 Hypoperfusion 
 Arteriogenic emboli 
Penetrating artery disease ("Lacunes")(25%) 
Cardiogenic embolism 
 Atrial fibrillation 
 Valve disease 
 Ventricular thrombi 
 Other 
 Cryptogenic stroke (30%) 
Other, unusual causes (5%) 
 Prothrombic states 
 Dissections 
 Arteritis 
 Migraine/Vasospasm 
 Drug abuse 
II. Primary Hemorrhage 
 Intraparenchymal 
 Subarachnoid (Gregory, et al.2002). 
Up to 90% of all strokes are  found to be ischemic in nature, while  10%  resulting from 
intracerebral hemorrhage or subarachnoid hemorrhage . The majority of ischemic strokes are 
found to be  of arterial origin such as atherothrombosis— which is a  generalized, diffuse and 
progressive polyvascular disease. In most of acute ischemic strokes, unstable angina, acute 
MI, sudden cardiac death, and peripheral arterial disease (PAD), atherothrombosis have a key 
role (Balucani, et al., 2010). 
PATHOPHYSIOLOGY  
 Stroke is defined as an "acute neurologic dysfunction of vascular origin with sudden 
(within seconds) or at least rapid (within hours) occurrence of symptoms and signs 
corresponding to the involvement of focal areas in the brain" (Goldstein, et al., 1989).      
The two main types of stroke are ischemic and hemorrhagic, accounting for approximately 
85% and 15%, respectively (Hickey, 2003).When an ischemic stroke occurs, the blood 
supply to the brain is interrupted, and brain cells are deprived of the glucose and oxygen they 
need to function. Ischemic stroke is a complex entity with multiple etiologies and variable 
clinical manifestations. Approximately 45% of ischemic strokes are caused by small or large 
artery thrombus,20% are embolic in origin, and others have an unknown cause (Hickey, 
2003). Thrombosis can form in the extracranial and intracranial arteries when the intima is 
roughened and plaque forms along the injured vessel. The endothelial injury (roughing) 
permits platelets to adhere and aggregate, then coagulation is activated and thrombus 
develops at site of plaque. Blood flow through the extracranial and intracranial systems 
decreases, and the collateral circulation maintains function. When the compensatory 
mechanism of collateral circulation fails, perfusion is compromised, leading to decreased 
perfusion and cell death. During an embolic stroke, a clot travels from a distant source and 
lodges in cerebral vessels. Microemboli can break away from a sclerosed plaque in the 
carotid artery or from cardiac sources such as atrial fibrillation, patent foramen ovale, or a 
hypokinetic left ventricle (Hickey, 2003). Emboli in the form of blood, fat, or air can occur 
during surgical procedures, most commonly during cardiac surgery, but also after long bone 
surgeries (Warlow et al., 2001).Less common causes of ischemic stroke include carotid 
dissection (Bader & Littlejohns, 2004) and the presence of coagulopathies, such as those 
resulting from antiphospholipid antibodies (APASS Investigators, 2004). Other causes 
include arteritis, infection, and drug abuse, such as the use of cocaine (Blank-Reid, 1996; 
Hickey, 2003). While still not completely understood, the presence of periodontal disease 
and tooth loss is also an associated risk for ischemic stroke (Joshipura, Hung, Rimm, 
Willett, & Ascherio, 2003). As a thrombosis or emboli cause a decrease in blood supply to 
the brain tissue, events occur at the cellular level, referred to as the ischemic cascade. 
Neurons and support cells require a careful balance of variables such as temperature, pH, 
nutrition, and waste removal in their environment to function optimally (Hinkle & Bowman, 
2003). Intensive basic scientific research during the last two decades has given healthcare 
professionals an increased understanding of the ischemic cascade in the format of the precise 
environmental alterations involved in the pathophysiology of ischemic injury at the cellular 
level. Understanding the ischemic cascade has led to the concept of a therapeutic time 
window for treatment possibilities. Often, there is a core region of dead cells surrounded by 
an area of hypoperfused tissue. The hypoperfused area may be rescued; this area is referred to 
as the penumbra region (Muir et al., 2006). Neuroprotection is a broad term that refers to 
pharmacological and nonpharmacological treatments used to halt the cellular events in the 
ischemic cascade, forming the theoretical basis for many of the acute stroke therapies under 
study (Lees, et al., 2006) as well as the rationale for intervening within a therapeutic time 
window following ischemic stroke. 
 
TREATMENT FOR ISCHEMIC STROKE  
Initial management 
The initial management of acute ischemic stroke involves medical stabilization, 
including airway protection and ventilatory and hemodynamic support, followed by 
neurologic assessment, brain imaging, and evaluation of the appropriateness of thrombolytic 
therapy.  
 
Airway and ventilatory support: 
Patients with acute stroke are at risk for respiratory failure from aspiration and 
pneumonia, often in the setting of difficulty in protecting the airway and clearing secretions 
because of facial or bulbar weakness or an altered level of consciousness. Hypoxemia may 
worsen the injurious effects of cerebral ischemia, and patients must be monitored closely with 
a goal to keep oxygen saturation greater than 95%. If a patient requires endotracheal 
intubation, short-acting sedatives should be used, and the hemodynamic changes associated 
with intubation should be minimized. No prospective trials have been undertaken to establish 
the ideal mode of ventilation in intubated stroke patients. A commonly used mode for 
patients who are awake but in need of airway protection is pressure support ventilation, 
whereas synchronized intermittent mandatory ventilation or assist control ventilation is 
recommended for patients who have intracranial hypertension or are comatose. Excessive 
positive end-expiratory pressures may be deleterious in patients with elevated intracranial 
pressure (ICP) .Mechanically ventilated patients frequently require sedation; however, 
sedatives may cause hypotension and additional brain injury by lowering cerebral perfusion 
pressure . Propofol, popular because of its short duration of action, has been associated with a 
‗‗propofol infusion syndrome‘‘ when used at high doses for prolonged periods 
(Vasile, et al., 2003). This syndrome originally was described in pediatric patients, but it also 
can occur in adults. It presents with metabolic acidosis, rhabdomyolysis, hypotension, 
bradyarrhythmias,and death . Frequent discontinuation of sedatives is indicated to monitor 
carefully for changes in the patient‘s neurologic status. 
 
Blood pressure and fluid management: 
 
 Patients with acute ischemic stroke often have elevated blood pressures in the first 
few days after symptom onset. Elevated blood pressure may occur for a variety of reasons, 
including physiologic compensation for cerebral ischemia, increased ICP, pain, or long-
standing underlying hypertension . Advantages of treating hypertension in acute ischemic 
stroke include concerns for hemorrhagic transformation of the ischemic infarct and 
worsening cerebral edema. Lowering blood pressure may compromise cerebral blood flow in 
the area surrounding the infarct, resulting in stroke extension. In normotensive individuals, 
cerebral blood flow is maintained over a wide range of mean arterial pressures (50–150 mm 
Hg) . Chronically hypertensive patients require a higher range of mean arterial pressures to 
maintain normal cerebral  blood flow . Because many stroke patients have long-standing 
hypertension, blood pressure lowering may result in cerebral hypoperfusion and worsening of 
ischemia. It is generally accepted that elevated blood pressures should not be lowered, unless 
the patient has received thrombolytic treatment; has a hypertensive emergency (aortic 
dissection, hypertensive encephalopathy, acute renal failure, acute pulmonary edema, or acute 
myocardial infarction); or has another contraindication to elevated blood pressure, such as 
recent surgery. In the absence of controlled clinical trials, the American Stroke Association 
guidelines recommend that antihypertensive agents should be withheld unless the systolic 
blood pressure is greater than 220 mm Hg or the diastolic blood pressure is greater than 120 
mm Hg . If patients have received thrombolytic therapy, the guidelines advocate maintaining 
systolic blood pressure less than or equal to 180 mm Hg and diastolic blood pressure less than 
or equal to 105 mm Hg. If blood pressure lowering is indicated, it should be instituted 
cautiously to avoid hypotension. A variety of intravenous agents maybe used to lower blood 
pressures.Adrenergic blocking agents (labetalol), calcium channel blockers (nicardipine), and 
angiotensin-converting enzyme inhibitors (enalaprilat) are preferred in patients with acute 
stroke because these agents are less likely to cause cerebral vasodilation and ICP elevation, 
effects that might be anticipated with sodium nitroprusside or hydralazine .Some patients 
with acute cerebral ischemia resulting from severe extracranial or intracranial vessel stenosis 
may benefit from induced hypertension . Typically, mean arterial pressure is increased 20% 
to 25% from baseline using intravenous isotonic fluids, phenylephrine, dopamine, or 
norepinephrine, while the patient‘s neurologic status and hemodynamic stability are 
monitored closely. The impact of this therapy on stroke outcome is being evaluated in 
ongoing clinical trials. In patients with ischemic brain injury, a key therapeutic goal is to 
maximize brain perfusion and collateral blood flow to the injured area. It is important to 
assess the patient‘s volume status and correct any dehydration.Stroke patients may be 
dehydrated on admission, and many of them cannot tolerate intake of oral fluids, normal 
saline infusions are therefore started immediately. Hypotonic fluids should be avoided 
because these may contribute to worsening of cerebral edema and increased ICP . 
 
Neurologic examination: 
 
Assessing the patient for neurologic deficits may be accomplished in an efficient and 
reproducible manner by using the National Institutes of Health Stroke Scale (NIHSS). This is 
a series of neurologic tests designed to assess the patient‘s level of alertness; comprehension; 
and motor, sensory, visual, and language function (Caulfield and Wijman, 2008). 
 
Treatment of acute ischemic stroke 
 
1. Thrombolytic therapy 
  
 Thrombolytic therapy for acute ischemic stroke was first proposed in the 
1950's;however intracranial hemorrhage was such a ,limiting factor that use of thrombolytic 
as a therapy became dormant until just recently, when better understanding about brain 
hemorrhage, use of plasminogen activators, and better imaging techniques have shed new 
light on this type of therapy in acute ischemic stroke (Dumo, et al., 1997).The therapeutic 
effect of tissue plasminogen activators are to activate plasmin and thereby lyse fresh 
thromboemboli.Agents include streptokinase,anisolysed plasminogen streptokinase activator 
complex (APSAC),and tissue plasminogen activator (t-PA) single chain (alteplase) 
(Bradberry and Fagan, 2002). 
 
2. Anticoagulants 
Anticoagulants reduce the formation of fibrin clots. Three major types of 
anticoagulants are available: heparin and related products, which must be used 
parentrally;direct thrombin inhibitors,which also must be used parentrally;and the orally 
active coumarin derivatives(eg.warfarin) have been developed. Direct thrombin inhibitors 
include Lepirudin is a recombinant form of the leech protein hirudin and Bivalirudin is a 
modified form of hirudin. 
 
3. Antiplatelet agents: 
 
Antiplatelet drugs (aspirin, dipyridamole, clopidogrel, ticlopidine, prasugrel 
abciximab, eptifibatide, and tirofiban) act on specific targets to inhibit platelet activation and 
aggregation .Clopidogrel effectively inhibits Adenosinediphosphate induced platelet 
activation and aggregation by selectively and irreversibly blocking the P2Y12 receptor on the 
platelet membrane. Aspirin acts by irreversibly acetylating the cyclooxygenase (COX-1) 
enzyme, thus suppressing the production of thromboxane A2 (TXA2) and inhibiting platelet 
activation and aggregation.. (Balucani, et al., 2010) 
 
4. Mannitol 
 Mannitol,an osmotic diuretic may be administered intravenously to reduce intracranial 
pressure. 
 
5. Surgical therapy: 
Generally the goal of surgical procedure is to remove the source of occlusion and /or 
embolus and hopefully to increase cerebral blood flow to the ischemic area. 
 
Carotid endartectomy (CEA) is the most common surgical procedure used for 
occlusive cerebrovascular disease. This procedure has been popular since its introduction 
over 30 years ago.  
 
REHABILITATION 
 
Rehabilitation helps the person gain back lost abilities to become more independent. It 
usually begins while the patient is still in acute care. For many patients, it continues 
afterward, either as a formal rehabilitation program or as individual rehabilitation services. 
Many decisions about rehabilitation are made by the patient, family, and hospital staff before 
discharge from acute care.Rehabilitation includes physiotherapy,speech therapy and 
occupational therapy.  
 The goal in rehabilitation is to improve function so that the stroke survivor can 
become as independent as possible. This must be accomplished in a way that preserves 
dignity and motivates the survivor to relearn basic skills that the stroke may have taken away 
- skills like eating, dressing and walking ( National Stroke Association, 2012). 
Risk Factors for Ischemic Stroke  
Nonmodifiable Risk Factors or Risk Markers: 
Age, gender, race, ethnicity, and heredity have been identified as markers of risk for 
stroke. Although these factors cannot be modified, their presence helps identify those at 
greatest risk, enabling vigorous treatment of those risk factors that can be modified. Age is 
the single most important risk factor for stroke. For each successive 10 years after age 55, the 
stroke rate more than doubles in both men and women. Stroke incidence rates are 1.25 times 
greater in men, but because women tend to live longer than men, more women than men die 
of stroke each year. 
Potentially Modifiable Risk Factors for Ischemic Stroke 
 
Hypertension 
Hypertension is the single most important modifiable risk factor for ischemic stroke. 
Most estimates for hypertension indicate a relative risk of stroke of approximately 4 when 
hypertension is defined as systolic blood pressure ≥160 mm Hg and/or diastolic blood 
pressure ≥95 mm Hg. A summary of seven studies assigning a relative risk of 1 for borderline 
or mild hypertension determined the relative risk to be about 0.5 at a blood pressure of 
136/84 mm Hg and about 0.35 at a blood pressure of 123/76 mm Hg (MacMahon and 
Rodgers, 1994). From the lowest to the highest level of blood pressure in this summary, risk 
is increased about 10-fold. Although clearly important even in the elderly, the impact of 
hypertension may decrease with age: the odds ratio is 4 at age 50, decreasing to 1 by age 90. 
From population surveys the prevalence of hypertension is about 20% at age 50, about 30% 
at age 60, 40% at age 70, 55% at age 80, and 60% at age 90 .When the Joint National 
Committee V definition is used (≥140/90 mm Hg or on antihypertensive medication), 
prevalence increases to about 45% at age 50, >60% at age 60, and >70% at age 70. (National 
Center for Health Statistics, 1986). The prevalence of hypertension is greater in blacks than 
in whites. The efficacy of antihypertensive treatment has been well established in clinical 
trials. In a summary of 17 treatment trials of hypertension throughout the world involving 
nearly   50000 patients, there was a 38% reduction in all strokes and a 40% reduction in fatal 
stroke favoring systematic treatment of hypertension. This effect was true in whites and 
blacks and at all ages. Treatment was also highly effective in preventing stroke in elderly 
persons with isolated systolic hypertension, the most prevalent form of hypertension in 
persons older than 65. Importantly, there was no less impact on stroke prevention above age 
80, with incidence reduced by 40% (SHEP Cooperative Research Group, 1991). 
Cardiac disease 
Various cardiac diseases have been shown to increase the risk of stroke. Atrial 
fibrillation (AF) is the most powerful and treatable cardiac precursor of stroke. The incidence 
and prevalence of AF increases with age. With each successive decade of life above age 55, 
incidence of AF doubles (Benjamin, et al., 1994). Using data from four population-based 
studies and the US census, it has been estimated that 2.2 million Americans have intermittent 
or sustained AF. Prevalence above age 65 is estimated to be 5.9%. Data from the 
Framingham Study and hospital discharges suggest that the prevalence of AF in the US 
population is increasing. The aging of the population, the increasing incidence of AF with 
age, and the increasing prevalence of AF suggest that AF will result in increasing rates of 
morbidity and mortality in the population.  
Diabetes and Glucose Metabolism 
 
 Persons with diabetes have an increased susceptibility to atherosclerosis and an 
increased prevalence of atherogenic risk factors, notably hypertension, obesity, and abnormal 
blood lipids. Case-control studies of stroke patients and prospective epidemiological studies 
have confirmed an independent effect of diabetes with a relative risk of ischemic stroke in 
persons with diabetes from 1.8 to 3.0. Among Hawaiian Japanese men in the Honolulu Heart 
Program, those with diabetes had twice the risk of thromboembolic stroke of persons without 
diabetes that was independent of other risk factors (Burchfiel, et al., 1994). In a population-
based cohort, persons with diabetes had a risk-factor adjusted relative risk of stroke of 1.8 in 
men and 2.2 in women. In the Framingham study, persons with glucose intolerance had 
double the risk of brain infarction than that of nondiabetic persons.  
 In addition to the role of glucose status (normal, impaired glucose tolerance, or 
diabetic), there are other aspects of glucose metabolism that may play a role as a risk factor 
for ischemic stroke—specifically hyperinsulinemia and increased insulin resistance (the 
relative inability of insulin to enhance glucose disposal). Both were shown to be risk factors 
for ischemic stroke among subjects with normal glucose status (Shinozaki, et al., 1996). In 
non-Hispanic white and Hispanic subjects, increased insulin resistance is associated with 
increased atherosclerosis of the carotid arteries independent of glucose status, insulin levels, 
and other major cardiovascular risk factors (Howard, et al., 1996). 
Lipids 
 While hypercholesterolemia is an important modifiable risk factor for coronary heart 
disease, the link to ischemic stroke remains uncertain. However, data clearly support the 
positive relation between total and LDL cholesterol and a protective influence of HDL 
cholesterol on extracranial carotid atherosclerosis (Heiss, et al., 1991). In secondary analyses, 
the Scandinavian Simvastatin Survival Study (4S) found a reduction of fatal or nonfatal 
stroke with simvastatin versus placebo (RR=.70, 95% confidence interval .52, .96), and the 
Asymptomatic Carotid Artery Plaque Study (ACAPS) reported fewer strokes in the lovastatin 
versus placebo group (5 versus 0) (Simvastatin Survival Study, 1994). A pooled analysis of 
four pravastatin trials disclosed a 46% reduction in risk of stroke (P=.054) (Byington, et al., 
1995). 
Cigarette Smoking 
 Cigarette smoking increases risk (RR) of ischemic stroke nearly two times (Shinton, 
and Beevers, 1989), with a clear dose-response relation. In both the Framingham Study and 
the Nurses' Health Study (Kawachi, et al., 1993) cessation of smoking led to a prompt 
reduction in stroke risk—Major risk was reduced within 2 to 4 years. This reduction in risk 
occurred throughout the age spans of these studies and in heavy as well as moderate smokers.  
Alcohol 
 
 Moderate consumption of alcohol may reduce cardiovascular disease, including 
stroke. Recent epidemiological studies have shown a U-shaped curve for alcohol 
consumption and coronary heart disease mortality, with low to moderate alcohol consumption 
associated with lower overall mortality. In an overview analysis of stroke studies, a J-shaped 
association curve was suggested for the relation of moderate customary alcohol consumption 
and ischemic stroke. (Camargo, 1989). This was most consistent for white populations; 
however, little if any association existed for Japanese and possibly black populations. 
Increasing alcohol consumption increases risk for brain hemorrhage. (Gorelick, 1995). 
Illicit Drug Use 
 Drug abuse is a major social problem, with cocaine the substance most commonly 
associated with stroke (Kelly, et al., 1992). Other drugs linked to stroke include heroin, 
amphetamines, LSD, PCP, "T's and Blues," and marijuana. Case reports have also linked 
over-the-counter sympathomimetic decongestants, cold remedies, and diet aids (eg, 
phenylpropanolamine), ephedrine, and pseudoephedrine with hemorrhagic and, less often, 
ischemic stroke. The bulk of information about stroke and drug use and abuse is derived from 
case reports or case series, with many reports confounded by multiple drugs used. There are 
sparse epidemiological data relating drug use to stroke.  
Lifestyle Factors (Obesity, Physical Activity, Diet, and Acute Triggers) 
 Various lifestyle factors have been associated with increased stroke risk. These 
include obesity, physical inactivity, diet, and acute triggers such as emotional stress. Obesity 
has been associated with higher levels of blood pressure, blood glucose, and atherogenic 
serum lipids, which are independent risk factors for stroke. In the Framingham study, obesity 
defined as a Metropolitan Life chart relative weight greater than 30% above average was a 
significant independent contributor to incidence of brain infarction in men aged 35 to 64 and 
women aged 65 to 94. In the Honolulu Heart Study, obesity was identified as an independent 
factor related to stroke incidence. The pattern of obesity may be important; central obesity 
manifested by abdominal deposition of fat, rather than obesity involving the hips and thighs, 
has been related to the occurrence of atherosclerotic disease (Abbott, et al., 1994). 
Oral Contraceptives 
Oral contraceptives with an estrogen content >50 µg, the preparations used in the 
1960s and 1970s, were strongly associated with the risk for stroke. Recently a study of low-
dose oral contraceptives (<50 µg estrogen) disclosed no increased risk of stroke in more than 
3.6 million woman-years under observation (Petitti, et al., 1996). 
Migraine 
While migraine has been identified as an independent risk factor for ischemic stroke 
in men older than 40 in the Physicians' Health Study, no association was found in other 
studies after adjusting for other stroke risk factors (Buring, et al., 1995). Although there may 
be an association between migraine and stroke, this association must be put in the context of 
the absolute risk of stroke. It has been estimated that the presence of migraine increased the 
incidence of stroke in young women from 10 in 100 000 woman-years to 19 in 100 000 
woman-years. Therefore, the absolute risk of stroke associated with migraine is very small.  
Transient Ischemic Attacks 
 
The average risk of stroke in patients with TIAs is about 4%. After adjustment for 
major cardiovascular risk factors predisposing a patient to stroke, a TIA remains a significant 
independent risk factor for both stroke and myocardial infarction. TIA referable to a high-
grade carotid artery stenosis carries a higher risk for stroke than those beyond a mild stenosis, 
and the risk with hemispheric ischemic symptoms is greater than for retinal ischemia. Recent-
onset TIA has a higher risk for ischemic stroke than remote TIA, and the same may be true 
for "crescendo" TIA. Various other clinical features have a major effect on the absolute risk 
for individual patients . It is clear that antiplatelet therapy substantially reduces risk for stroke 
(and other atherothrombotic events such as myocardial infarction and vascular death) in all 
high-risk patients, including those with TIAs. (Sacco, et al.,1997) 
DRUGS AND MECHANISM OF ACTION 
 Revelation of the multiple mechanisms which are involved in platelet thrombus 
formation provides opportunities for selectively inhibiting the pathways most significant to 
the pathophysiology of atherothrombosis . Along with other secondary prevention measures, 
antiplatelet therapy remains a key component of atherothrombotic event prevention. 
Numerous trials and meta-analyses have confirmed the effect of an antiplatelet therapy to 
reduce the risk of vascular event recurrence in patients with previous stroke or TIA. 
However, controversies exist and the debate is now being focused on the optimal antiplatelet 
regimen. The majority of research in secondary stroke prevention supports the clinical value 
of aspirin. Whether aspirin remains the best available antiplatelet drug for stroke prevention 
and if it should be used alone or in combination with another antiplatelet agent more effective 
than aspirin monotherapy are still a matter of debate (Balucani, et al., 2010). 
 Antithrombotic drugs act by blocking the platelet aggregation and activation at many 
points in the thrombotic cascade.They consist of aspirin, thienopyridines (clopidogrel and its 
predecessor ticlopidine), intravenous GP IIb/IIIa inhibitors, which block the final common 
pathway of platelet activation and aggregation, unfractionated heparin and low-
molecularweight heparin, and direct thrombin inhibitors. Presently, available antiplatelet 
drugs (aspirin, dipyridamole, clopidogrel, ticlopidine, prasugrel abciximab, eptifibatide, and 
tirofiban) act on specific targets to inhibit platelet activation and aggregation .Clopidogrel 
effectively inhibits Adenosinediphosphate induced platelet activation and aggregation by 
selectively and irreversibly blocking the P2Y12 receptor on the platelet membrane. Aspirin 
acts by irreversibly acetylating the cyclooxygenase (COX-1) enzyme, thus suppressing the 
production of thromboxane A2 (TXA2) and inhibiting platelet activation and aggregation 
(Balucani, et al., 2010). 
 
MONO AND DUAL ANTIPLATELET THERAPY  
  Kral, et al conducted a study on characteristics of particular antiplatelet agents as 
well as choice of antiplatelet treatment in various situations, based on the evidence and 
international recommendations. The study site was Stroke Center, Department of Neurology, 
Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, 
Czech Republic and Department of Neurology, Central Military Hospital, Ruzomberok, 
Slovakia. The findings of the study were that Acetylsalicylic acid (ASA) is the only 
antiplatelet drug used in primary prevention, mainly to reduce the risk of myocardial 
infarction (MI), but also in women aged 45 years or more and in some patients with non-
valvular atrial fibrillation to reduce risk of IS/TIA.In the secondary prevention of 
noncardioembolic Ischemic stroke/Transient Ischemic Attack, ASA in combination with long 
release dipyridamole (DIP) and clopidogrel (CLOP) alone are considered first choice 
therapies. The choice of the particular antiplatelet agent should be individualized according to 
the patient risk factor profiles and treatment tolerance. ASA alone or triflusal can be used 
alternatively in patients who cannot be treated with either ASA+DIP or CLOP. The use of 
indobufen should be considered only in patients in need of temporary interruption of the 
antiplatelet therapy. Ticlopidine (TIC) should not be newly introduced into the treatment. 
Currently, insufficient data are available on the use of cilostazol in IS/TIA prevention. 
  
The results of recent clinical trials on the use of antiplatelet therapy suggest that 
patients with a history of stroke or TIA may constitute a population distinct from patients 
with coronary or peripheral vascular disease. This may be caused, in part, by the differing 
etiologies of stroke and the increased vulnerability of cerebral vessels to bleeding. Indeed, 
dual antiplatelet therapy, which has been found to be beneficial for the treatment of acute 
coronary syndromes and percutaneous coronary interventions, does not confer secondary 
stroke protection. The emerging paradigm is that some level of platelet inhibition is required 
for secondary stroke protection; a level beyond which increased risk of bleeding arises. 
James K. Liao, MD, 2007 suggested that since the vast majority of patients with ischemic 
stroke have recurrent stroke or transient ischemic attack, rather than myocardial infarction, as 
their next event, antiplatelet therapies for these patients should be administered according to 
what has been shown to be efficacious for secondary stroke protection rather than for 
myocardial protection. Combination therapies, which provide optimal platelet inhibition as 
well as vascular protection, may offer the best strategy for secondary stroke protection. 
 
 The fact that intensified antiplatelet therapy contributes to the reduction of major 
atherothrombotic complications in cardiovascular (CV) disease is widely accepted. In the 
setting of PCI (percutaneous coronary intervention) and acute coronary syndromes, dual 
antiplatelet therapy at optimal dosing and timing has significantly lowered the risk of 
thrombotic complications. There is a growing body of evidence that there is variability in 
response to antiplatelet treatments and this represents a potentially important clinical 
problem. 
 
Understanding the mechanisms underlying this phenomenon is important in 
improving patient care, but due to the diversity of factors involved, a clear predictive model 
for responsiveness to antiplatelet therapy is still missing. Attempts have been made to 
characterize the efficacy of antiplatelet therapy using platelet function testing but based on 
current information, its routine use is not recommended particularly as costs and cost 
effectiveness have not been established and agreement between laboratory methods is 
lacking. Hence, it is necessary to identify risk factors for decreased efficacy of standard 
antiplatelet drug treatment. It may be useful to adjust antiplatelet therapy based on individual 
risk assessment, especially as new platelet inhibitors are being introduced or are in 
development including prasugrel as well as the non-thienopyridines, ticagrelor, elinogrel, the 
ATP analog cangrelor, and thrombin receptor antagonists. The article focuses on antiplatelet 
therapy in those patients who are at high risk for cardiovascular events and discusses the 
options for individual risk assessment and strategies to personalize therapy in the light of the 
large number of recent developments. (Geisler, et al., 2010) 
 
 A prospective study of consecutive patients with acute stroke who were admitted to 
36 participating hospitals in China, India, Indonesia, Korea, Malaysia, the Philippines, 
Singapore, Taiwan, Thailand, and Vietnam was conducted with the use of a simple identical 
data sheet,  the demographics and cardiovascular risk factors of each patient was recorded. 
Early death was defined as death on discharge from the acute hospital. 2403 patients were 
enrolled with ischemic stroke and 783 patients with intracerebral hemorrhage. Among 
patients with ischemic stroke, previous use of antiplatelet drugs  and relatively young age 
group 56 to 75 years  were protective factors; atrial fibrillation, ischemic heart disease, 
diabetes (Jorgensen, et al., 1994), and ex-smoker status were risk factors for early death. 
Among patients with intracerebral hemorrhage, hypertension  and young age group 56to 75 
years old  were associated with lower death rate, whereas diabetes  was a risk factor for early 
death (Haffner, et al., 1998) .In Asian patients with stroke, previous use of antiplatelet drugs 
nearly halved the risk of early death in patients with ischemic stroke, whereas atrial 
fibrillation, ischemic heart disease, diabetes, and ex-smoker status were risk factors for early 
death (Broderick, et al., 1992). Among patients with intracerebral hemorrhage, diabetes was 
associated with early death, whereas young age group and hypertension were associated with 
lower death rates, though no clear explanation for the hypertension association could be 
discerned from the data available (Wong, 1999). 
 
 Clopidogrel along with aspirin for reduction of infarction in acute stroke or TIA with 
large artery stenosis and microembolic signals (CLAIR) trial was designed as a randomized, 
open-label and blinded-endpoint trial. Patients  with acute ischemic stroke or TIA who had 
symptomatic large artery stenosis in the cerebral or carotid arteries and in whom 
microembolic signals were detected on transcranial doppler between,were arbitrarily assigned 
within 7 days of symptom onset to receive clopidogrel (300 mg for the first day, then 75 mg 
daily) plus aspirin (75–160 mg daily) or aspirin alone (75–160 mg daily) for 7 days . On days 
2 and 7, microembolic signals on transcranial doppler monitoring was done.Proportion of 
patients with microembolic signals on day 2 were taken as primary endpoint .Out of 100 
patients,93 had symptomatic intracranial stenosis in either the intracranial internal carotid 
artery or the middle cerebral artery: 45 of 46 in the dual therapy group and 48 of 52 in the 
monotherapy group. At day 2, 14 of 45 patients in the dual therapy group and 27 of 50 
patients in the monotherapy group for whom data were available had at least one 
microembolic signal on transcranial doppler.Adverse events were found to be similar in both 
the groups. None of the patients had intracranial or severe systemic haemorrhage, except two 
patients in the dual therapy group who had minor haemorrhages. Combination therapy by 
means of clopidogrel and aspirin is more effective than aspirin alone in reducing 
microembolic signals in patients with predominantly intracranial symptomatic stenosis. 
Clinical trials are now essential to investigate whether this combination treatment also results 
in a reduction in stroke incidence (Wong, et al., 2010). 
 
 In 7599 high-risk patients with recent ischemic stroke or TIA and at least one 
additional vascular risk factor who were already receiving clopidogrel 75 mg/day, a trial was 
carried out to compare aspirin (75 mg/day) with placebo.The trial was designed as a 
randomized, double-blind, placebo-controlled trial. Period of treatment and follow-up was 18 
months.The primary endpoints included a composite of ischemic stroke, MI , vascular death, 
or rehospitalisation for acute ischemia (including rehospitalisation for transient ischemic 
attack, angina pectoris, or worsening of peripheral arterial disease).Analysis was by intention 
to treat which was done by means of log rank test and a Cox‘s proportional-hazards model. 
Compared with 636 (16·7%) in the clopidogrel alone group (relative risk reduction 6.4%, 
[95% CI –4·6 to 16·3]; absolute risk reduction was found to be 1% [–0·6 to 2·7] in the group 
receiving aspirin and clopidogrel, 596 (15.7%) patients reached the primary endpoint. Life-
threatening bleedings were found to be higher in the group receiving aspirin and clopidogrel 
whereas clopidogrel alone accounted for (96 [2·6%] vs 49 [1·3%]; absolute risk increase 
1·3% [95% CI 0·6 to 1·9]). Although major bleedings were found to be increased in the 
group receiving aspirin and clopidogrel no variation was recorded in mortality.It was found 
that addition of  aspirin to clopidogrel in high-risk patients with recent ischemic stroke or 
transient ischemic attack is linked with a non-significant difference in reducing major 
vascular events. On the other hand, the risk of life threatening bleeding was found to be 
increased by the addition of aspirin (Diener, et al., 2004). 
 
 Dual antiplatelet therapy is usually superior to mono therapy in preventing recurrent 
vascular events .A study was carried out to assess the safety and efficacy of triple antiplatelet 
therapy in comparison to dual therapy in reducing recurrent vascular events. Completed 
randomized controlled trials investigating the effect of triple versus dual antiplatelet therapy 
in patients with ischemic heart disease (IHD), cerebrovascular disease or peripheral vascular 
disease were identified using electronic bibliographic searches. Data were extracted on 
composite vascular events, myocardial infarction, stroke, death and bleeding and analyzed. 
Twenty-five completed randomized trials (17,383 patients with IHD) were involved which 
involved the use of intravenous GP IIb/IIIa inhibitors (abciximab, eptifibatide, tirofiban), 
aspirin, clopidogrel and/or cilostazol. In comparison with aspirin-based therapy, triple 
therapy using an intravenous GP IIb/IIIa inhibitor, significantly reduced composite vascular 
events and myocardial infarction in patients with non-ST elevation acute coronary syndromes 
(NSTE-ACS) and ST elevation myocardial infarction (STEMI). A significant reduction in 
death was also noted in STEMI patients treated with GP IIb/IIIa based triple therapy. 
Increased minor bleeding was noted in STEMI and elective percutaneous coronary 
intervention (PCI) patients treated with GP IIb/IIIa based triple therapy. Stroke events were 
too infrequent for us to be able to identify meaningful trends and no data were available for 
patients recruited into trials on the basis of stroke or peripheral vascular disease. Triple 
antiplatelet therapy based on intravascular GPIIb/IIIa inhibitors was more effective than 
aspirin-based dual therapy in reducing vascular events in patients with acute coronary 
syndromes (STEMI and NSTEMI). Minor bleeding was increased among STEMI and 
elective PCI patients treated with a GP IIb/IIIa based triple therapy. In patients undergoing 
elective PCI, triple therapy had no beneficial effect and was associated with an 80% increase 
in transfusions and an eightfold increase in thrombocytopenia. Insufficient data exist for 
patients with prior ischemic stroke and peripheral vascular disease (Geeganage, et al., 2010). 
  
Stroke is the most common neurological disease in China, and antiplatelet 
treatment is important for primary and secondary prevention.A study was conducted to 
describe the current status of antiplatelet treatment before, immediately after, and 1 month 
after ischemic stroke in the Qingdao area of China, and to determine the factors and 
potential barriers influencing use. A total of 1114 patients with acute ischemic stroke were 
enrolled from 11 hospitals in the Qingdao area.The frequency of antiplatelet treatment was 
6.4% before the stroke, 91.5% in hospital, and 77.2% at 1 month. Aspirin pretreatment 
was independently associated with higher education level, higher income level, history of 
hyperlipidemia, and history of cerebral vascular disease. Antiplatelet treatment in hospital 
was independently associated with treatment in an urban hospital, National Institutes of 
Health Stroke Scale at onset, and statin use in hospital. Antiplatelet treatment at 1-month 
follow-up was independently associated with higher income level, diagnosis of transient 
ischemic attack, antiplatelet treatment in hospital, large artery atherosclerosis,and statin 
use at follow-up. Modified Rankin Scale ≥4 at 1-month follow-up and history of coronary 
heart disease were negatively associated with antiplatelet treatment at follow-up. This 
study documents the current status of antiplatelet treatment in primary and early secondary 
prevention of ischemic stroke in China (Xin, et al., 2011). 
 
 Aspirin, dipyridamole and clopidogrel are effective in secondary vascular prevention. 
Combination therapy with three antiplatelet agents might maximise the benefit of antiplatelet 
treatment in the secondary prevention of ischemic stroke. A randomized, parallel group, 
observer-blinded phase II trial compared the combination of aspirin, clopidogrel and 
dipyridamole with aspirin alone. Adult patients with ischemic stroke or transient ischemic 
attack (TIA) within 5 years were included.One recurrent stroke occurred in a patient in the 
triple group who was noncompliant of all antiplatelet medications. The number of patients 
with adverse events and bleeding complications, and their severity, were significantly greater 
in the triple therapy group: Long term triple antiplatelet therapy was associated with a 
significant increase in adverse events and bleeding rates, and their severity, and a trend to 
increased discontinuations. However, the patients had a low risk of recurrence and future 
trials should focus on short term therapy in high risk patients characterized by a very recent 
event or failure of dual antiplatelet therapy (Sprigg, et al., 2008). 
 
  A systematic review was performed to define the relative and absolute risk of 
clinically relevant adverse events with the antiplatelet agents, aspirin and clopidogrel. 
Relative risks (RR) were determined by meta-analysis of 22 trials for aspirin versus placebo 
and from single studies for aspirin versus clopidogrel, aspirin versus aspirin/clopidogrel, and 
clopidogrel versus aspirin/clopidogrel.Aspirin increased the risk of major bleeding, major 
gastrointestinal (GI) bleeding, and intracranial bleeding versus placebo. No difference 
between 75-162.5 mg/day and _162.5-325 mg/day aspirin versus placebo was seen. The 
absolute annual increases attributable to aspirin were major bleeding: 0.13%; major GI 
bleeding: intracranial bleeding: 0.03% (Derry and Loke, 2000). No study compared 
clopidogrel with placebo. One study showed increased major GI bleeding (but not non-GI 
bleeding endpoints) with aspirin (Yusuf, et al., 2001). Low-dose aspirin increases the risk of 
major bleeding by _70%, but the absolute increase is modest: 769 patients need to be treated 
with aspirin to cause one additional major bleeding episode annually. Compared with 
clopidogrel, aspirin increases the risk of GI bleeding but not other bleeding; however, 883 
patients would need to be treated with clopidogrel versus aspirin to prevent one major GI 
bleeding episode annually at a cost of over 1 million dollars (McQuaid and Laine, 2006). 
 
 Evidence for the effectiveness of dual antiplatelet therapy in stroke is inadequate. 
Patients with symptomatic carotid stenosis are at high danger of early recurrent stroke. In this 
group, asymptomatic microembolic signals (MES), detected by transcranial Doppler 
ultrasound (TCD), are considered to be the markers of future stroke and TIA.They suggest a 
substitute marker to assess antiplatelet therapy, however no multicenter study has evaluated 
the practicability of this approach. Clopidogrel and Aspirin for Reduction of Emboli in 
Symptomatic Carotid Stenosis (CARESS) is a randomized, double-blind study conducted in 
subjects with recently symptomatic _50% carotid stenosis (De Bray and Glatt, 1995). 
Patients were first screened with TCD, and in case MES were detected, they were treated 
with clopidogrel and aspirin or aspirin monotherapy.TCD recordings were  repeatedly made 
on days 2 and 7. Microembolic signals were detected in 110 of 230 patients out of them 107 
were randomized.On day 7, 43.8% of dual-therapy patients were MES positive when 
compared with 72.7% in monotherapy patients. The secondary end point of MES frequency 
per hour was reduced when compared with baseline) by 61.4% in the dual-therapy group at 
day 7 and by 61.6% on day 2. There were 4 recurrent strokes and 7 TIAs in the monotherapy 
group in opposition to no stroke and 4 TIAs in the dual-therapy group .In patients with recent 
symptomatic carotid stenosis, combination therapy with clopidogrel and aspirin was found to 
be more effective than aspirin alone in reducing asymptomatic embolization (Markus, et al., 
2005). 
 
  
  
 
 
 
 
 
 
 
 
                Methodology 
METHODOLOGY 
 
Objective 
The study was aimed to determine whether addition of aspirin to clopidogrel could 
have a greater benefit than clopidogrel alone in prevention of secondary vascular events in 
patients after TIA or ischemic stroke. 
Study design  
It was a retrospective observational study with duration of six months. 
Study setting 
The study was conducted in the  Department of  Neurology, Kovai Medical Center 
and Hospital, a multi speciality hospital in Coimbatore, Tamil Nadu. 
Study period 
The study was conducted over a period of six months from June 2011 to December 
2011. 
Study population  
Patients diagnosed with stroke attending the Neurology Clinic between January 2009 
to January 2010, conforming to the study criteria. 
Study criteria 
Inclusion criteria  
Patients of age > 40 years who are diagnosed with ischaemic stroke and treated with 
either  mono (Clopidogrel) or dual (Clopidogrel +Aspirin) antiplatelet therapy. 
Exclusion criteria 
a) Patients who are less than 40 years of age. 
b) Patients who are diagnosed with hemorrhagic stroke. 
Sources of data 
Data were collected from patients' case reports and treatment charts. 
Study protocol 
Ethical committee approval for conducting the study was obtained from Kovai 
Medical Center and Hospital. Records of patients on antiplatelet therapy from January 2009 
to January 2010 were studied. Patients who met the study criteria were included in the study. 
Demographic characteristics of the patient including age, sex, occupation, smoking habits 
were collected. The other necessary findings like type of stroke, history of stroke, past 
medication history, type of antiplatelet therapy prescribed, number of recurrences were noted 
from patient's case reports and treatment charts. Data were entered in the data entry sheet. 
Analysis was based on the first recurrence of a cardiovascular event which was taken as the 
primary endpoint at any point during the follow-up period. The follow up period was taken as 
18 months. 
Statistical analysis 
Demographic characteristics of the study population were expressed in percentage. 
Relative risks and associations were determined by using the 'chi-square test'. Values of P ≤ 
0.05 were considered to be significant.  
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
         Results 
RESULTS 
 In this retrospective study, the effectiveness of mono and dual antiplatelet therapy in 
secondary prevention of vascular events was evaluated in a total of 38 patients with ischemic 
stroke. The identified patients were either on aspirin plus clopidogrel (dual) or only 
clopidogrel (mono) antiplatelet therapy. 
 Among the stroke patients, visiting the neurology clinic, 34.2 % of patients were 
found to have recurrence of vascular events after the study period. The mean age of the study 
population was found to be 61.36 years. In the population identified, the number of male 
patients were found to be 30 and female patients were 8 (Table 1, Figure 1). 
 The age of onset of the study population was found to be varying from 41 to 90 years. 
About 31% of the total study population, were in the age group of  61-70 years and they 
constituted the highest percentage of the total patients.29% were found to be in the 51-60 age 
group and 20% in the age group of 71-80 years.In the age group of 41-50,the percentage was 
14% and 6% were noted in 81-90 age group. (Table 2,Figure 2). Mean age of patients taking 
dual therapy was found to be 61 and mean age in mono group was 64. In dual therapy group, 
31% of patients had Ischemic stroke as qualifying event compared to 5 % in monotherapy. 
 In the male population, 86.6 % were prescribed dual therapy and 13.3 were prescribed 
with monotherapy (Table3,Figure3).In the female group, 87.5 % were prescribed dual 
therapy and 12.5 % were given monotherapy (Table 4,Figure 4). 
 In the total study population, 86.8 % were having hypertension as the risk factor.52.6 
% patients were identified to be having diabetes and 28.9 % of patients had a previous history 
of stroke 60.5% had hypercholesterolemia and 10.5% were smokers (Table 5, Figure 5). 
 The mean age of the patients being prescribed dual therapy was found out to be 60.93 
and mean age of the patients taking monotherapy was found to be 64.2 (Table 6).According 
to TOAST classification,2% were found to be having cardioembolism, 20% were having 
large artery atherothrombosis,12 % with small vessel occlusion in dual therapy group.20 % 
had cardioembolism and 60 % had small vessel occlusion in mono group (Figure 6). 
 Previous ischemic stroke, hypertension, diabetes, hypercholestrerolemia were found 
to be the most common risk factors in the population studied. Previous ischemic stroke were 
reported in 12 % of dual therapy group and 1% in mono group. Hypertension was found in 30 
% of dual group and 3 % of mono group. Diabetes was found to be a risk factor in 16% of 
dual therapy patients and 4% in monogroup. Hypercholesterolaemia was identified as risk 
factor in 19% of dual group and 4 % of mono group.11% of dual therapy patients and 2 % of 
mono therapy patients were smokers (Figure 7). 
 Out of the total study population, 36 patients had ischemic stroke as the qualifying 
event and 2 patients were having Transient Ischemic Attack. The event rate for ischemic 
stroke in dual therapy group was found to be 35.48 % and 0.2% for TIA. The event rate for 
TIA was found to be 0.5 % in dual group. The event rate was found to be 31.2 % in dual 
therapy group in patients whose age is greater than 61 and 41.1% in patients of age greater 
than or equal to 61 compared to the 33.3 % in mono group. The event rate in dual therapy 
group for males was found to be 42.3 % and 0.25 % in mono group. The event rate in dual 
therapy group for females was found to be 14.2 %.In patients having hypertension 0.4 % 
event rate was noted in dual therapy compared to 33.3 % in monotherapy. Diabetes patients 
had 0.25 % event rate in dual therapy and 0.25 % in monotherapy. Event rate in patients with 
previous ischemic stroke was found to be 1% in dual therapy and 1 % in monotherapy  
(Table 7). 
 The frequency of primary endpoint event was found out from the plot between the 
follow up period in months and number of patients at risk. The number of patients at risk of 
primary endpoints was found to be more increase in the follow up period in patients receiving 
dual therapy than those on mono therapy (Figure 8). 
 Univariate analysis of factors affecting primary endpoint showed that there was an 
association between recurrence of cardiovascular event and factors like gender, hypertension, 
previous ischemic stroke and antiplatelet therapy. Out of the total study population,8 patients 
having age less than 61 had recurrence with a p value  < 0.20.In the age group ≥ 61, five 
patients were  found to have recurrence.12 male patients and 1 female patient were found to 
have recurrence with a p value < 0.01.In patients with hypertension,13 cases of recurrences 
were found with a p value < 0.01.In patients with diabetes,5 cases were recorded with a p 
value < 0.7.In dual therapy group 12 cases of recurrences were noted compared to 1 case in 
mono therapy group with a p value <0.01 (Table 8). 
 The relative risk for recurrence were found out in the study population. In patients 
having ischemic stroke as qualifying event the relative risk of dual therapy was found to be 
1.7742 times that of mono therapy. When TIA was the qualifying event, the relative risk was 
found to be the same for both mono and dual therapy. Relative risk with dual therapy was 
0.9412 times than that of mono therapy in patients of age < 61 years and 1.2353 times in age 
≥ 61 years. In male patients, relative risk with dual therapy was 1.6923 times than with mono 
therapy and in females it was found to be 0.7500 times that of monotherapy. Patients with 
hypertension had 0.9744 times the risk and those with previous ischemic stroke had 1.2821 
times risk than with mono therapy. The relative risk in patients having diabetes was found to 
be equal in both dual and mono therapy (Table 9) 
 
  
 
 
 
 
 
 
 
 
       Tables and Graphs 
   
TABLE 1: Gender wise distribution of total study population 
Sl. No Gender Percentage of patients 
1. Male 79% 
2. Female 21% 
 
 
FIGURE 1: Gender wise distribution of total study population 
 
 
 
 
 
 
 TABLE 2: Age wise distribution of the study population 
 
 
FIGURE 2: Age wise distribution of the study population 
 
 
 
 
 
 
Sl. No Age group Percentage of patients 
1. 41-50 14 
2. 51-60 29 
3. 61-70 31 
4. 71-80 20 
5. 81-90 6 
 TABLE 3: Type of Antiplatelet therapy prescribed in male patients. 
MALE 
Sl.No Antiplatelet therapy prescribed Percentage of patients 
1. DUAL 86.6 
2. MONO 13.3 
 
Dual : Aspirin + Clopidogrel 
Mono: Clopidogrel 
FIGURE3: Type of Antiplatelet therapy prescribed. 
 
 
 
 
TABLE 4: Type of Antiplatelet therapy prescribed in female patients. 
FEMALE 
Sl.No Antiplatelet therapy prescribed Percentage of patients 
1. DUAL 87.5 
2. MONO 12.5 
 
Dual : Aspirin + Clopidogrel 
Mono: Clopidogrel 
FIGURE4: Type of Antiplatelet prescribed. 
 
 
 
 
 
 
TABLE 5: Risk factors and medical history of the study population. 
Sl.No Risk factors percentage of patients 
1. Hypertension 86.8 
2. Diabetes 52.6 
3. 
Previous ischemic stroke(before 
qualifying event) 
28.9 
4. Hypercholesterolemia 60.5 
5. Smoking 10.5 
 
 
FIGURE 5: Risk factors and medical history of the study population. 
 
 
 
 
 
 
TABLE 6: Baseline characteristics of the study population. 
Data are expressed as number (%) or mean ± SD 
 
 DUAL (n=33) MONO (n=5) 
MEAN AGE (years ± S.D) 
 
60.93 ± 11.45 
 
64.2 ± 20.64 
 
QUALIFYING EVENT 
 
  
IS 
 
31(93.9) 
 
5(1) 
 
TIA 
 
2(6) 
 
0 
 
TOAST 
CLASSIFICATION 
 
  
Cardioembolism 
 
2(6) 
 
1(20) 
 
Large-artery 
atherosclerosis 
 
20(60.6) 
 
0 
 
Small-vessel occlusion 
 
12(36.3) 
 
3(60) 
 
Stroke of other determined 
cause 
 
- - 
Undetermined cause 
 
- - 
RISK FACTORS AND 
MEDICAL HISTORY 
 
  
Previous IS 
(before qualifying event) 
12(36.3) 
 
1(20) 
 
Hypertension 
 
30(90.9) 
 
3(60) 
 
Diabetes 
 
16(48.4) 
 
4(80) 
 
Hypercholesterolaemia 
 
19(57.5) 
 
4(80) 
 
Past or current smoker 
 
11(33.3) 
 
2(40) 
 
 
 
  
FIGURE 6: Characterization of the study population according to the                        
TOAST CLASSIFICATION  
 
 
 
TOAST CLASSIFICATION 
 
 
 
 
 
 
 
 
 
 FIGURE 7 : Characterization of the study population on the basis of Risk factors and 
                    medical history 
 
 
 
 
 
 
 
 
 
 
 
 
 FIGURE 8 : Frequency of primary endpoint event 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE 7 : Rates of primary endpoint event in specified subgroups 
 
 
Subgroup   
EVENT RATE (%) 
 
  
number(n) 
 
DUAL 
 
MONO 
 
Qualifying event 
 
IS 
 
36 
 
35.48 
 
0.2 
 
 
TIA 
 
2 
 
0.5 
 
0 
 
Age(years) 
 
<61 
 
18 
 
31.2 
 
0 
 
 
≥61 
 
20 
 
41.1 
 
33.3 
 
Sex 
 
Female 
 
8 
 
14.2 
 
0 
 
 
Male 
 
30 
 
42.3 
 
0.25 
 
Hypertension 
 
No 
 
5 
 
0 
 
0 
 
Yes 
 
33 
 
0.4 
 
33.3 
 
Diabetes 
 
No 
 
18 
 
47 
 
0 
 
 
Yes 
 
20 
 
0.25 
 
0.25 
 
Previous IS 
 
No 
 
25 
0 
 
0 
 
 
Yes 
 
13 
 
1 
 
1 
 
 
 
 
 
 
 
 
 
TABLE 8 :Univariate analysis of factors affecting primary event 
 
Subgroup Recurrence 
 
Non recurrence 
 
P value 
 
Age < 61 
 
8 
 
15 
 
 
< 0.20 
 Age ≥ 61 
 
5 
 
10 
 
Male 
 
12 
 
18  
< 0.01 
 Female 
 
1 
 
7 
 
Hypertension 
 
YES 
 
13 
 
20  
< 0.01 
 NO 
 
0 
 
5 
Previous IS 
 
YES 
 
13 
 
0  
< 0.01 
 NO 
 
0 
 
25 
Diabetes 
 
YES 
 
5 
 
11  
< 0.7 
 NO 
 
8 
 
10 
Therapy 
 
MONO 
 
1 
 
4  
< 0.01 
 DUAL 
 
12 
 
21 
 
 
 
 
 
 
 
 
 
 
TABLE 9 : Relative risk of primary endpoint in different subgroups on dual and mono     
          antiplatelet therapy. 
 
 
Subgroup 
Relative risk 
 
95% CI 
 
P value 
 
Ischaemic stroke 
 
1.7742 
 
0.2886 -10.9086 
 
0.5361 
 
TIA 
 
1.0000 
 
0.104 - 9.6139 
 
1.0000 
 
Age < 61 
 
1.9412 
0.141 - 26.7183 
 
0.6200 
 
Age ≥ 61 
 
1.2353 
 
0.2261 - 6.7498 
 
0.8073 
 
Male 
1.6923 
 
0.2924 - 9.7948 
 
0.5570 
 
Female 
 
0.7500 
0.04558 - 12.3407 
 
0.8404 
 
Hypertension 
 
0.9744 
 
0.41 - 2.3153 
 
0.9531 
 
Previous IS 
 
1.2821 
 
0.5717 - 2.8748 
 
0.5465 
 
Diabetes 
 
1.0000 
 
0.1499 - 6.6709 
 
1.0000 
 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
          Discussion 
  
DISCUSSION 
 
 Stroke is an enormous and serious public health problem. Not only is it a common 
cause of death but also it is a major cause of disabilty among adults. Approximately, 20 
million people suffer from stroke each year and out of these 5 million do not survive. 
Developing countries account for 85% of global deaths from stroke. Stroke causes functional 
impairments, 20% survivors require institutional care after 3 months and disability occurs in 
15-30% (Balucani, et al., 2010). Ischemic stroke is found to be the principal universal cause 
of disability in the developed world, and the third leading cause of mortality. It is expected 
that 8–12% of individuals are found to die within the first 30 days of their initial stroke, and 
patients who survive the initial attack face an enlarged risk of successive vascular events and 
stroke, as approximately one-quarter of all strokes occurring each year are found to be 
recurrent. 21.5% of patients are found to be experiencing either a recurrent stroke or a 
transient ischemic attack (TIA) within the first year following the initial attack  
(Diener and Wong, 2008). Our results showed that out of the total patients, 34.2% had 
recurrence of vascular events. 
 Official census data from the United Kingdom in 1981, 1991, and 2001 have 
persistently shown inequalities in ischemic stroke mortality among the South Asian 
population. According to the 3 cross-sectional studies based on the national census data in the 
United Kingdom, the average standard mortality ratios (SMR) in South Asians were 55% and 
41% higher in males and females, respectively when compared with the white population 
(Gunarathne, et al., 2009). 
 
  In a Prospective Community-Based Study of Stroke in Kolkata, India (Das, et al., 
2007), Out of the screened population of 52 377 (27 626 men, 24 751 women), the age 
standardized prevalence rate of stroke to world standard population was 545.10 (95% CI, 
479.86 to 617.05) per 100 000 persons. The age standardized average annual incidence rate to 
world standard population of first-ever-in-a-lifetime stroke was 145.30 (95% CI, 120.39 to 
174.74) per 100 000 persons per year. Thirty-day case fatality rate was 41.08% (95% CI, 
30.66 to 53.80). Women had higher incidence and case fatality rates. 
 
  In our study the age of the study population varied from 41 to 90 years and the mean 
age of the study population was found to be 61.36 years. In the population identified, the 
number of male patients were found to be 78.94% and female patients were 21 %. 
 A randomized, double-blind, placebo-controlled trial revealed that  the most prevalent 
risk factors at randomization were hypertension (78%), diabetes mellitus(68%) and 
hypercholesterolemia (56%). 26% of patients had previous ischemic stroke and 19% had 
transient ischemic attack. Most patients had one additional risk factor, as defined in the 
inclusion criteria at study entry, and 20% had two or more (Diener, et al.,2004). In our total 
study population, 86.8 % were having hypertension as the risk factor, 52.6% patients were 
identified to be having diabetes and  34.2 % of patients had a previous history of stroke. 
Previous ischemic stroke, hypertension, diabetes, hypercholesterolemia were found to be the 
most common risk factors in the population studied. Previous ischemic stroke was reported in  
12 % of dual therapy group and 1% in the mono group. Hypertension was found in 30 % of 
dual group and 3 % of mono group. Diabetes was found to be a risk factor in 16% of dual 
therapy patients and 4% in monogroup. Hypercholesterolemia was identified as risk factor in 
19% of dual group and 4 % of mono group.11% of dual therapy patients and 2 % of mono 
therapy patients were smokers. 
  The only South Asian studies (Syed, et al., 2003) that classified their stroke 
population according to the TOAST taxonomy found a higher prevalence of lacunar strokes 
(42.7% and 68%) compared with large vessel infarctions (26% and 10%). In our study, 
according to TOAST classification, majority of the patients were found to have large artery 
atherothrombosis (Gunarathne, et al., 2009). 
 Of the 700,000 strokes that occur yearly in the United States, 200,000 are recurrent 
events. The risk of recurrent stroke has been reported as 11.5% at 7 days, 6% to 15% at 30 
days, and 18.5% at 3 months. Following a transient ischemic attack (TIA), the estimated risk 
of recurrent stroke was 8% at 7 days, 11.5% at 1 month, and 17.3% at 3 months. However, in 
our study, out of the total study population, 36 patients had ischemic stroke as the qualifying 
event and 2 patients were having Transient Ischemic Attack. The event rate for ischemic 
stroke in dual therapy group was found to be 35.48 % and 0.2% for TIA. The event rate for 
TIA was found to be 0.5 % in dual group (Kiwon, et al., 2007). 
 
In a MATCH trial conducted in 507 centres, the event rates for the primary endpoint 
in different predefined patient subgroups indicated a slight favour for adding aspirin to 
clopidogrel compared with placebo to clopidogrel in most subgroups. No interactions were 
reported between covariates and treatment effect, apart from patient age and treatment effect 
(Diener, et al., 2004). In our study, the relative risk for recurrence were obtained from  the 
study population and our results indicate a favour for monotherapy (clopidogrel alone) 
compared to dual (clopidogrel + aspirin). In patients having ischemic stroke the relative risk 
of dualtherapy was found to be 1.7742 times than that of dual therapy. The relative risk was 
found to be the same for both mono and dual therapy in patients having TIA. Relative risk 
with dual therapy was 0.9412 times than dual therapy in patients of age < 61years and 1.2353 
times in age ≥ 61 years. In male patients, relative risk with dualtherapy was 1.6923 times than 
that with mono therapy and in females it was found to be 0.7500 times that of mono. Patients 
with hypertension had 0.9744 times the risk and those with previous ischemic stroke had 
1.2821 times risk than with mono therapy. The relative risk in patients having diabetes was 
found to equal in both dual and mono therapy.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                            Conclusion 
CONCLUSION 
 
The aim of the study was to determine whether addition of aspirin to clopidogrel 
could have a greater benefit than clopidogrel alone in the prevention of secondary vascular 
events in patients after TIA or ischemic stroke. Out of the total patients, 34.2 %  of patients 
had recurrence of vascular events. 36.3 % patients reached the primary endpoint in the group 
receiving dual therapy compared to 20% in the monotherapy group. 31% in dual therapy 
group had Ischemic stroke as qualifying event compared to 5 % in monotherapy. 
Our study focused on the prevalence of risk factors in patients with recurrence of 
vascular events. Risk factors found were previous ischemic stroke in 12 % of dual therapy 
group and 1% in mono group. Hypertension was found in 30 % of dual group and 3 % of 
mono group. Diabetes was risk factor in 16% of dual therapy patients and 4% in monogroup 
Hypercholesterolemia was found in 19% of dual group and 4 % of mono group11% of dual 
therapy patients and 2 % of mono therapy patients were smokers. 
   In our study, we also observed the prescribing trends in patients, and noted that dual 
therapy was found to be more prominent than monotherapy. Dual therapy did not appear to 
have any added advantage over monotherapy as the event rate of recurrence of vascular event 
were more in patients under dual therapy. The primary events were found to have a 
significant association with gender, risk factors and therapy. No bleeding complications were 
observed in the study population. 
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           Annexures 
   
   
DATA ENTRY FORM 
Name of Patient: 
…………………………………………………………………………………. 
Date of admission …… / …… /…… Time ……………  IP No: …………………….. 
Address:……………………………………………………………….……………….............. 
Contact number: ....…………………………………………………………………………. 
Age in years :  30-50         50-70            70-90 
Sex :  M   F 
Occupation: None    Housewife  Agriculture  Business 
                      Govt employee  Student  Other   Unknown 
Family income:           upto 60,000  60,000-1,80000                  1,80000 and above 
 
Antiplatelet therapy prescribed:     Clopidogrel                Clopidogrel+Aspirin 
Brands and dose of antiplatelets: …………………………………………………………… 
Stroke subtype:   Ischemic    Embolic 
Recurrence of Stroke :  YES    NO 
If yes, fill the following: 
No. of recurrences:  Nil  1  2  3 and above 
Frequency of recurrence during treatment ……………………………………………….. 
………………………………………………………………………………………………… 
Risk factors :  Hypertension  Diabetes mellitus  Smoking 
   Alcoholism  Cardiac diseases    
   Dyslipidemias  
 
Duration of treatment :  1-2 years                  3-4 years                   above 5 years 
